
11 Jan 2019 Research
Leukaemia: Investigating stem cells to prevent cancer
What is this research looking at?
The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.
Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.
Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.
I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.
What could this mean for people with leukaemia?
This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.
Related posts
4 August 2020
Our life-saving work must continue
Leukaemia and other blood cancers don’t stop for coronavirus (COVID-19) and our vital research and care must continue
21 May 2020
A new clinical trial announced
A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.
25 June 2019
Championing groundbreaking therapies and emotional support
We are proud to be at the forefront of funding innovative research into gene therapy treatments
25 August 2020
Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK
After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.